Fermiscan's development program includes conducting clinical research to allow further advancement of the technology and identify the optimum applications of the technology for disease diagnosis.

In 2008 the validation trial was completed which enables Fermiscan to focus on advancement of the Fermiscan Test and building the knowledge base through several international clinical studies. These studies are in progress or planned to be run in conjunction with leading clinical institutions in Singapore, Italy, Japan and Australia.

In June 2008 the results from a small open study to detect breast cancer analysed hair from 35 women, confirmed to have either early breast cancer or diagnosed with metastatic disease, (which involves the spread of cancer from the breast to other organs of the body), demonstrated a sensitivity of 84 per cent. In this small study, the indications for the test for metastatic disease are encouraging but larger numbers are required before firm conclusions can be drawn.

It may be possible to use the Fermiscan Test to detect other forms of carcinoma. Early data from the original scientist has indicated that this is may be possible (as disclosed in Fermiscan's US patent) but further samples are needed to confirm the finding and to determine the sensitivity and specificity of the assay.

Back to top